Plus   Neg

Ashland Global Slips To Loss In Q2

Ashland Global Holdings Inc. (ASH) reported that its second-quarter net loss was $582 million or $9.61 per share compared to net income of $76 million or $1.19 per share in the prior-year quarter, hurt primarily by the previously-disclosed non-cash goodwill impairment charge following the business unit realignment that occurred during the quarter.

Adjusted income from continuing operations was $52 million or $0.84 per share, up from $0.83 in the prior-year quarter. Adjusted income from continuing operations excluding intangibles amortization expense was $69 million, consistent with the prior-year quarter, or $1.12 per share, up from $1.08 in the prior-year quarter.

Sales for the quarter declined to $610 million from $667 million in the prior year.
Analysts polled by Thomson Reuters expected the company to report earnings of $0.81 per share and revenues of $618.76 million. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hyundai Motor has launched a new IONIQ brand dedicated to battery electric vehicles, as the automaker is accelerating its efforts to gain a share in the fast-growing global EV market. Under the IONIQ brand, Hyundai plans to introduce three new dedicated electric vehicle models over the next four years. Hyundai is South Korea's largest automaker. Amazon.com, Inc. is in talks with mall operator Simon Property Group, Inc. to use the abandoned anchor departmental stores of JC Penny and Sears at their malls as fulfillment centers, reports said. This is expected to help the e-commerce giant in boosting their last mile delivery, which is the last leg of the delivery process. The U.S. Food and Drug Administration announced the approval of Trevena Inc.'s Olinvyk (oliceridine), a new opioid for intravenous use in hospitals or other controlled clinical settings. Olinvyk is an opioid agonist to manage moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.
Follow RTT